Friday, 13 January 2017

Medical automation market growth is expected to reach USD 79.4 billion by 2024

The global medical automation market is expected to reach USD 79.4 billion by 2024, according to a new report by Grand View Research, Inc. The increasing demand for accuracy and reproducibility required during medical procedures is the high impact rendering driver for the medical automation market. 
The rising adoption of these devices is attributed to the advantages associated with automated systems. For example, the automation of tedious tasks such as sampling, monitoring of quality, quantity, packaging and labeling, and scanning of medicines and devices, have reduced human efforts and increased speed and accuracy, which has led to increased dependency on these automated systems. 
Medical Automation Market Growth
Moreover, the growing global prevalence of chronic conditions such as diabetes, cancer, arthritis, and chronic obstructive pulmonary disease (COPD) is further pushing the demand for therapeutic, laboratory and pharmacy automated medication systems, which are faster and more productive. As per the World Health Organization (WHO) estimates, cardiovascular diseases (CVDs) is the leading cause of mortality around the globe; in addition, an exponential rise has been witnessed in the diabetes cases from 108 million in 1980 to 422 million in 2014. The aforementioned factors are responsible for creating the need for automated medical equipments over the forecast period. 
Furthermore, with the advent of technologically advanced defibrillators and ablation therapies, this market is expected to gain swift growth in its market share in the near future. For instance, automation in the following pharmacy-based functions, medication dispensing, storage, and retrieval enables traceability and tracking, which in turn improves patient safety and reduces errors. Furthermore, there is an increased focus on incorporating automation in hospitals due to the associated benefits, such as reduction of errors and operational costs; these factors altogether are expected to present this market with high growth opportunities in the near future.
View summary of this report, click the link below: 
Further key findings from the study suggest:
  • The therapeutic segment was observed to dominate in terms of revenue share in 2015owing to the high usage rate of automated devices in the non-surgical procedures, such as external defibrillators, an implantable cardioverter, and wearable/ implantable drug pumps 
  • On the other hand, the medical logistics and training segment is expected to grow at a lucrative CAGR of over 10.0%. The rising adoption of advanced systems, such as Pneumatic Tube Systems (PTS) used in material transportation and Real Time Location System (RTLS) in location-tracking, contributes towards the overall medical automation market growth during the forecast period. 
  • The research laboratories and institutes segment is also identified as a lucrative segment due to, the rising demand for automated research laboratories that are helpful in the detection and the treatment of chronic diseases. These laboratory automated systems help in reducing demand and supply gaps by mechanization, which yields rapid results and increases overall productivity. This is expected to further enhance its usage over the forecast period. 
  • With an aim to address the increasing demand for advanced molecular diagnostic techniques in cancer, the Leiden University Medical Center have recently succeeded in isolating DNA and RNA from small tissue samples using a high-throughput, fully automated solution by Siemens. Innovations like these are expected to present the market with significant growth opportunities. 
  • Some key players in this industry include Accuray, Inc., Tecan Group Ltd., Medtronic Plc., Swisslog Holding AG, GE Healthcare, Intuitive Surgical, Inc., Stryker Corporation, Siemens AG, Koninklijke Philips N.V., and Danaher Corporation. 
  • These industry players are adopting strategies such as technological innovation, new product launches, and strategic collaborations including mergers and acquisitions to capitalize untapped opportunities. For instance, in July 2015, Medtronic Plc. acquired RF Surgical Systems, Inc., for further expansion of its business and with the aim of capturing a huge market share of the medical automation market in the coming years. 
To get full details at: 

Thursday, 12 January 2017

Biosimilars market growth is expected to reach USD 41.7 billion by 2024

The biosimilars market is expected to reach USD 41.7 billion by 2024, according to a new report by Grand View Research, Inc. The global biosimilars market is anticipated to witness a marked growth during the period of 2016 to 2024. The most significant factor leading to the growth of this industry is the fact that major biological drugs are nearing the patent cliff. Further, the lower cost of these drugs as compared to the patented biologics, the increasing encumbrance to cut down healthcare costs across the medical systems in the world, and the favorable clinical outcomes demonstrated through clinical trials for the biosimilar drugs is expected to boost the industry.
For the purpose of this study, the major countries considered are the U.S., Canada, the UK, Germany, India, China, Brazil, and Russia. It was estimated that in 2015, Europe accounted for the largest market share of the global biosimilars market, followed by Asia Pacific.
The industry is segmented on the basis of type of products and applications. With regard to the product type, the recombinant non-glycosylated segment is projected to flourish rapidly during the study period. On the other hand, the recombinant glycosylated proteins segment is estimated to grow at a significant CAGR during the period 2015 to 2024 due to the increasing, wide spread incidence of cancer cases (24 million by 2035), which is identified as the crucial factor driving the growth of this sector.
view summary of this report, click the link below: 
Further key findings from the study suggest:
  • North America is anticipated to be the fastest growing market during the forecast period. The biosimilars market has gained significant momentum in the U.S., presenting new opportunities for R&D and the manufacturing sector of biosimilars.
  • The European market is the most advanced one as it has been the first to formulate a regulatory pathway and adopt the use of biosimilars for more than 8 years now. Germany accounts for the maximum share in the biosimilars industry, followed by the rest of the European countries (UK, France, Spain, and Italy).
  • The Asia Pacific market is expected to witness a lucrative growth during the period 2015 to 2024. India and China are the key countries identified that are expected to lead the industry growth in the study period.
  • The market for oncology is estimated to soar at a rapid pace in accordance with the increasing incidence of cancer cases in the world. Additionally, the demand for cost-effective cancer treatments is expected to further fuel the industry growth.
  • The biosimilars market comprises several local as well as global players. Some major players of this market include Amgen, Inc., Beacon Ltd., Tea Pharmaceutical Industries Ltd., Merck & Co., Milan, Inc., Dr. Reddy’s Laboratories, Inc., Sandoz, Inc., and Celltrion Healthcare Co., Ltd. 
Reference Links: 

Orthopedic devices market size is expected to reach USD 43.1 billion by 2024

The global orthopedic devices market is expected to reach USD 43.1 billion by 2024, according to a new report published by Grand View Research, Inc. Major drivers of the market include the rising demand for orthopedic surgeries owing to the growth in road accidents and the prevalence of orthopedic diseases. 

The introduction of new products made of materials, such as various types of ceramics and polymers, has led to a rise in the success rates of surgeries. In addition, these products are available at affordable costs and customizable sizes and shapes. As a result, the adoption of these advanced products is swiftly increasing. In addition, the rising geriatric population prone to orthopedic diseases, such as osteoporosis and arthritis, is augmenting the growth of the market. 
Hip and knee applications together accounted for the largest market share in 2015. A relatively high rate of hip and knee replacement surgeries coupled with the constant innovations in the treatment of hip and knee injuries is contributing towards the growth of these application segments. 
Stringent regulatory approval procedures are the prime factors restraining the growth of the market. In addition, a high device cost and expensive surgical costs are some other factors impeding the market growth.
To request a sample copy or view summary of this report, click the link below: 
http://www.grandviewresearch.com/industry-analysis/orthopedic-devices-market
Further key findings from the study suggest:
  • The knee orthopedic devices segment captured the largest share of the market in 2015. This was attributed to the factors such as a high rate of knee surgeries including common knee injuries to total knee replacements.
  • The hip orthopedic devices segment was the second largest market in 2015. The large portfolio for hip injury management is expected to result in a significant share in the global market.
  • North America captured the largest market share of 51.4% in 2015 and is expected to maintain its dominance over the forecast period. The presence of a large number of major market players and a high adoption rate of advanced technologies are the factors driving the growth of the market in the region.
  • The Asia Pacific market is expected to witness a lucrative CAGR of 8.6% during the forecast period. The presence of a large untapped market and the availability of supportive government regulations are expected to attract the attention of the global players.
  • Some major players in the orthopedic devices market include NuVasive, Inc., Medtronic PLC, Zimmer-Biomet Holdings, DePuySynthes, Stryker, Aesculap Implant Systems, LLC, Donjoy, Inc., and Conmed Corporation
Reference Links:

Erectile dysfunction drugs market size is expected to reach USD 3.2 billion by 2022

The global erectile dysfunction drugs market is expected to reach USD 3.2 billion by 2022 according to a new report by Grand View Research Inc. Rising adoption of sedentary lifestyle and increasing prevalence of conditions causing erectile dysfunction such as stress, hypertension, and related medications are the key factors expected to widen the target population base for this market. 
However, the market is estimated to witness decline in revenue over the forecast period. Expiration of key drugs from 2017 to 2019 is likely to curb revenue growth. On the other hand, the market is likely to open up new avenues for the generic manufacturers to capitalize on. The increasing risk of sexually transmitted diseases, narrowing of insurance coverage for erectile dysfunction treatment, growing threat from counterfeit drugs, and presence of social stigma in developing countries are some factors limiting penetration rates. 
view summary of this report, click the link below:  
Further key findings from the report suggest:
  • Viagra accounted for over 47.0% of the total revenue in 2014. It is generally considered as the first line of treatment for erectile dysfunction. Brand loyalty and advantages associated with this drug such as high efficacy, and effectiveness are the major factors attributing for its large market share.
  • Cialis (tadalafil) from Eli Lilly & Co. and Levitra (vardenafil) from Bayer AG are known to be the competitors for Viagra globally. Cialis (tadalafil) was approved in 2003 by the U.S. FDA, as a prescription drug in the U.S. Cialis is also known as “The Weekend Pill” owing to its 36-hour effectiveness.
  • After the patent expiration of key drugs such as Cialis (tadalafil) in 2017 and Levitra (vardenafil) in 2018, other drugs such as Stendra/Spedra, Zydena (udenafil), and Vitaros (Alprostadil Cream) are expected to capture the market share during the forecasts period.
  • North America constituted the largest share of approximately 55.0% in 2013 of the total erectile dysfunction market. Extension of patent exclusivity rights for Viagra (sildenafil citrate) in the U.S. till 2019 along with introduction of new erectile dysfunction drugs such as Zydena (udenafil) and Stendra/Spedra (avanafil) will be the major factors responsible for market growth during the forecasts period.
  • Asia Pacific accounted for a revenue share of over 16.5% in 2012 owing to the presence of a lucrative market for generic drugs, untapped opportunities, and increasing awareness related to erectile dysfunction in this region
  • Apricus Biosciences Inc., Cristalia Produtos Quimicos Farmaceuticos Ltd., Bayer AG, Dong-A Pharmaceutical Co. Ltd., Meda Pharmaceuticals, Inc., Eli Lilly and Company, Pfizer, Inc., S.K. Chemicals Co. Ltd., and Vivus, Inc. are some major players of this market
  • Extensive R&D carried out by companies and high unmet needs in developing economies are expected to boost industrial growth. Key manufacturers are targeting regions with unmet clinical needs by entering into agreement with local manufacturers and distributors. Key players are constantly engaged in developing novel drugs in an attempt to improve the presence and ensure sustainability. 

Reference Links:

Contraceptives Market is expected to reach USD 30.86 million by 2022

Global Contraceptives Market is expected to reach USD 30.86 million by 2022, according to a new study by Grand View Research Inc. Growing prevalence of sexually transmitted infections (STIs), especially HIV and the introduction of new products exhibiting improved efficacy are expected to drive the contraceptives market over the forecast period. The presence of high unmet contraceptive needs coupled with the implementation of favorable government policies is expected to significantly contribute towards the growth of the contraceptives industry.

In 2014, contraceptives device was the largest product segment with revenue estimated at over USD 12.0 billion. Devices such as condoms and contraceptive sponges, which are relatively inexpensive and easy to use, are expected to spearhead market growth over the forecast period. Female condoms are also expected to gain penetration rates over the next seven years. Growing user awareness levels and improving product availability are two key factors expected to drive segment growth.
view summary of this report, click the link below:
http://www.grandviewresearch.com/industry-analysis/contraceptives-market
Further key findings from the study suggest:
  • Condoms are identified as the most lucrative sub segment of the contraceptive devices market. Low prices and abundant product availability are two key factors expected to drive the condoms market over the forecast period. The fact that, condoms are effective in preventing sexually transmitted diseases and unwanted pregnancies is also expected to boost usage rates.
  • Intrauterine devices, especially hormonal IUDs are expected to experience attractive growth over the forecast period. Growing demand for Mirena, Jaydess and Skyla and the commercialization of Liletta is expected to further drive segment growth.
  • The North American contraceptives market accounted for the largest revenue share in 2014. Presence of sophisticated healthcare infrastructure, high user awareness levels and abundant product availability are key factors attributing to the region’s market position.
  • Latin America is expected to spearhead future market growth. Numerous government programs and free distribution of samples within the region are expected to help manufacturers capitalize on the available opportunities.
  • Asia Pacific is also expected to witness substantial growth during the forecast period owing to, rapidly rising population levels and the consequent rise in demand for contraception. Presence of government initiatives in countries such as India, China, Sri Lanka, Pakistan, and Bangladesh aimed at slowing down population growth and prevalence of STDs are expected to promote market growth.
  • Key players of the contraceptives market include Reckitt Benckiser Plc, Mayer Laboratories, Actavis Plc, Church & Dwight, Pfizer Inc., Merck & Co., The Female Health Company and Teva Pharmaceuticals.
Reference Links:

Medical image analysis software market is expected to reach USD 4.5 billion by 2024

The medical image analysis software markethttp://www.grandviewresearch.com/press-release/global-medical-image-analysis-software-market is expected to reach USD 4.5 billion by 2024, according to a new report by Grand View Research, Inc. The clinical urgency to incorporate medical image analysis software for the diagnosis of chronic diseases is presumed to fuel the market growth throughout the forecast period. Moreover, the increased use of electronic health records to efficiently store, manage, and distribute patient health information in the form of medical images is also contributing towards the market growth.  Additionally, continuous advancements in the technology, such as computer-aided diagnosis (CAD) are expected to provide potential growth opportunities for the utilization of the new and improved medical image software tools in a wide range of disease application areas including cancer and urology.


The steady demand for diagnostic and treatment procedures with greater efficiency have consequentially boosted the industry share of the medical image analysis software tools with enhanced features. Improved image quality, high resolution, and multi-modal imaging platforms are the key associated benefits driving the physician preference, thereby fuelling the market demand. Furthermore, the incorporation of the software tools facilitates sharing of medical image records among physicians to facilitate rapid and accurate treatment delivery, thus the implied demand for the medical image analysis software systems. These aforementioned factors are expected to drive the emergence of the medical image analysis software market over the forecast period.
Further key findings from the study suggest:
  • On the basis of software type, the stand-alone software segment is anticipated to grow at a lucrative CAGR of over 7.5% over the forecast period due largely to the associated benefits, such as the systems with a user-friendly interface in use, which eliminates the requirement of skilled workforce to operate these systems
  • In terms of modality, ultrasound imaging is expected to register a lucrative growth rate of over 8.9% in the coming eight years. According to a report by NCBI, the ultrasound imaging segment can detect around 92.5% of the breast lumps. Moreover, the use of high-frequency radiation is not involved, thus ensuring patient safety; the high diagnosis efficiency and patient safety factors are anticipated to further fuel this segment’s demand.
  • On the basis of applications, the cardiology segment is expected to register the fastest growth owing to the rising in corporation of medical imaging systems used for the diagnosis of cardiovascular diseases (CVDs), such as Merge Cardio, which integrates digital health records from various cardiology-based modalities thus furnishing cardiologists with comprehensive patient record files with additional features, such as remote location access, along with the high prevalence rate of the CVDs synergistically accelerating the growth of this segment.
  • Diagnostic centers are anticipated to grow at a lucrative CAGR amongst the end-use market segment as a consequence of the increasing number of imaging diagnostic labs and the government initiatives in this direction. For example, Moldovan Ministry of Health along with International Finance Corporation are trying to attract private sector investors through public-private partnerships to set up and modernize radiology and diagnostic imaging.
  • As of 2015, North America dominated the regional medical image analysis software market at over 33.0%as a result of the presence of leading industry players and the supportive reimbursement policies. The rising government funding directed towards improving the imaging facility is also a prime growth driver for this regional market.
  • Asia Pacific is expected to be growing at the fastest CAGR of over 9.0% during the forecast period due to the rising penetration of the medical imaging systems in fast emerging economies of the Asia pacific region, such as China and India, investments in the healthcare industry, high R&D intensity by the major market players, and the presence of untapped opportunities
  • Some key players catering to this industry are Philips Healthcare, Siemens Healthineers, Toshiba Medical Systems Corporation, ClaroNav, Inc., GE Healthcare, Agfa Gevaert Corporation, Spacelabs Healthcare, Inc., Aquilab GmbH, MIM Software, Inc., Merge Healthcare, Inc., Carestream Health, Inc., Esaote, Inc., Bruker Corporation, and Xinapse Systems Ltd.
  • These market players are adopting strategies, such as technological innovation, new product development, and strategic collaborations as well as mergers & acquisitions to maximize their industry share. In August 2015, GE Healthcare received an FDA approval for its low dose Computed Tomography for lung cancer screening thereby expanding its product portfolio.
Reference Links: 

Tuesday, 10 January 2017

Medical Sensors Market Size Excepted To Reach $18.5 Billion By 2024

The medical sensors market is expected to reach USD 18.5 billion by 2024, according to a new report by Grand View Research, Incite upsurge in the number of patients afflicted with chronic conditions, such as diabetes and hypertension, is fueling the usage of monitoring as well therapeutic devices, thus boosting the market demand. 

The target population for this market is patients with chronic illnesses, as such conditions necessitate regular checkups and intermittent or continuous patient monitoring. The rise in population of chronically ill patients further increases the uptake of the medical sensors. 
The geriatric population is highly prone to developing chronic disorders and they pose a higher risk of developing age-related deformities and complications. Moreover, the adoption of unhealthy food habits and sedentary lifestyles and the resultant surge in the incidence of obesity has led to the increasing prevalence of lifestyle disorders including diabetes. The presence of a large target population base combined with the prevalence of lifestyle-related risk factors is likely to accelerate the growth of the medical sensors market during the forecast period. 
Technological advancements in terms of accuracy, portability, and affordability associated with the new generation medical sensors resulted in the increased usage of these devices; for instance, the introduction of easy-to-operate, home-based diagnostic kits that are cost effective.  
Further key findings from the study suggest:
  • The biosensors products segment held a lucrative share of over 40.0% in 2015. This is ascribable to the following attributes of the novel biosensors: durability, reliability, and accuracy. Moreover, their applications in the healthcare areas, such as the detection of drug abuse, glucose monitoring for diabetes, the detection of cholesterol, and others. All these elements governed the growth of this segment in 2015. 
  • The surgical applications of the sensors dominated the market in 2015. Whereas, the monitoring applications segment is projected to be the fastest growing during the forecast period. Advancements, such as wearable technology are anticipated to boost the demand for the monitoring devices market. 
  • The hospitals registered a remunerative growth in 2015; this can be attributed to the presence of a well-developed healthcare infrastructure, which yields faster and accurate diagnosis. Moreover, the availability of well-equipped infrastructure coupled with the presence of skilled personnel and technologically advanced equipments contribute towards the lucrative growth of this segment. 
  • North America held a considerably large share of over 35.0% in 2015 owing to the presence of leading sensor manufacturers, a well-planned medical reimbursement network, and the increasing disposable income 
  • On the contrary, Asia Pacific is anticipated to be the fastest growing region with a CAGR of over8.0% over the forecast period. The favorable economic developments and the advancing healthcare system with the aid of supportive government initiatives are anticipated to further assist the growth. Moreover, the increasing base of the aging population in this region also, additionally impels the demand. According to the report published by the Ministry of Statistics, in India, 8.6% of the total population is aged above 60; hence, presenting a profitable opportunity for the market players to invest in this region. 
  • The leading players of the medical sensors market include Analog devices, Inc., Avago technologies Ltd., Danaher Corporation, GE Measurement &Control Solutions, Inc., Honeywell International, Inc., Stellar technologies, Inc., OmniVision Technologies, Inc., Sensation AG, TE Connectivity Ltd., Micro-Epsilon Messtechnik GmbH Co. & KG, and NXP Semiconductors N.V.
Reference Links: